Cereno Scientific announces new patent issued in Mexico for Phase II drug candidate CS1

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the Company’s leading drug candidate CS1’s first patent family has obtained an issued patent in Mexico. This further strengthens the intellectual property rights for CS1, that is in late Phase II development for pulmonary arterial hypertension (PAH).

“I am pleased to report that our leading drug candidate CS1 has obtained a patent issued by the Mexican authorities. Mexico is a large global pharmaceutical market, and as such an important future market for Cereno Scientific. This is an important milestone as it further expands the patent protection for CS1 as we shape the future commercial strategy for CS1, which will be supported also by robust clinical data,” says Sten R. Sörensen, CEO at Cereno Scientific.

CS1:s first patent family is titled “Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors”. The patent number assigned is 407925. The patent will be valid through 2032, with the possibility of patent extension of up to five years.

Cereno Scientific has during the last few months reported positive findings from the ongoing study suggesting a potential positive clinical benefit of drug candidate CS1 in patients with the severe rare disease PAH. Study completion and top-line results are expected during Q3 2024. 

For further information, please contact:

Henrik Westdahl, Director IR & Communications

Email: henrik.westdahl@cerenoscientific.com

Phone: +46 70-817 59 96

Sten R. Sörensen, CEO

Email: sten.sorensen@cerenoscientific.com

Phone: +46 73-374 03 74

About Cereno Scientific AB

Cereno Scientific develops innovative treatments for common and rare cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q3 2024. Since January 2024, we are delighted that the FDA´s Expanded Access Program will enable patients with PAH, a serious life-threatening disease condition, to gain access to CS1 where no comparable alternative therapy options are available. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding, which also has been recognized in the medical community. CS585 was in-licensed from the University of Michigan in 2023. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.